News articles about CareDx (NASDAQ:CDNA) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CareDx earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.7113250232239 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

CDNA has been the topic of a number of research reports. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Craig Hallum restated a “buy” rating and set a $10.00 price target (up from $4.00) on shares of CareDx in a research note on Monday, October 9th. Raymond James Financial, Inc. upgraded CareDx from a “market perform” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, September 27th. ValuEngine upgraded CareDx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $7.00 price target (up from $3.00) on shares of CareDx in a research note on Tuesday, September 26th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $6.69.

CareDx (NASDAQ:CDNA) traded up $0.10 during trading on Friday, hitting $6.60. The stock had a trading volume of 200,200 shares, compared to its average volume of 350,917. CareDx has a 1-year low of $0.76 and a 1-year high of $6.69. The company has a debt-to-equity ratio of -124.53, a quick ratio of 0.35 and a current ratio of 0.55.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02. CareDx had a negative return on equity of 157.00% and a negative net margin of 84.14%. The business had revenue of $12.19 million for the quarter, compared to analyst estimates of $12.05 million. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. analysts predict that CareDx will post -0.83 EPS for the current year.

In related news, major shareholder Neil Gagnon acquired 21,448 shares of the business’s stock in a transaction dated Monday, August 28th. The shares were acquired at an average price of $2.77 per share, with a total value of $59,410.96. Following the completion of the transaction, the insider now owns 903,731 shares of the company’s stock, valued at $2,503,334.87. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have bought 38,586 shares of company stock worth $121,792 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/caredx-cdna-given-news-impact-score-of-0-24/1724166.html.

About CareDx

CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.

Insider Buying and Selling by Quarter for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.